DATE: May 9th, 2017
TIME: 7:00AM PDT, 10:00AM ET, 2:00PM GMT
Early detection and elimination of new chemical entities with cardiac or hERG liability could substantially improve drug safety and minimize the cost of development. In this webinar, we will highlight different assays for validating ion channel inhibition using cell lines and cardiac toxicity using induced pluripotent stem cells (iPSCs).
High-throughput screening for in vitro potency evaluation of cardiac ion channel inhibitors on the FLIPR Tetra® System
Learning Objectives:
Multi-parameter in vitro assessment of compound effects on cardiomyocyte physiology using induced pluripotent stem cells
Learning Objectives: